Liposarcoma — the most common soft tissue sarcoma of adulthood, accounting for approximately 20% of all soft tissue sarcomas and representing a biologically diverse family of malignancies arising from adipogenic precursor cells, with approximately 2,000–2,500 new cases diagnosed annually in the United States — encompasses four major subtypes whose molecular identities, anatomic distributions, and clinical behaviors differ so profoundly that they are best understood as related but distinct diseases sharing a lineage commitment to fatty differentiation: well-differentiated liposarcoma (WDLPS, representing approximately 45–50% of cases, characterized by MDM2 and CDK4 gene amplification within supernumerary ring or giant marker chromosomes derived from chromosome 12q13–15, an indolent but locally aggressive behavior with near-zero metastatic potential, and near-universal occurrence in the retroperitoneum and deep soft tissues of the extremity), dedifferentiated liposarcoma (DDLPS, representing approximately 18–20% of cases, sharing MDM2/CDK4 amplification with WDLPS but featuring transition to a high-grade non-lipogenic sarcoma component with 15–20% metastatic risk, arising most commonly in the retroperitoneum as a primary dedifferentiated tumor or as focal dedifferentiation within a WDLPS at recurrence), myxoid liposarcoma (MLPS, representing approximately 30–35% of cases, defined by the pathognomonic FUS-DDIT3 fusion gene from t(12;16)(q13;p11) in approximately 90–95% of cases or less commonly EWSR1-DDIT3 from t(12;22)(q13;q12), occurring predominantly in the extremity — particularly the thigh — of young adults in the third and fourth decades, carrying a distinctive sensitivity to radiation therapy and trabectedin, and harboring a round-cell component (>5% round cells) that carries a significantly worse prognosis), and pleomorphic liposarcoma (PLPS, representing approximately 5% of cases, characterized by complex karyotype without MDM2/CDK4 amplification or FUS-DDIT3 fusion, occurring in older adults, carrying the highest metastatic risk across liposarcoma subtypes at 30–40%, and conferring a 5-year disease-specific survival of approximately 60% for localized disease). Overall 5-year survival across all liposarcoma subtypes ranges from near-complete for resected WDLPS (approaching 90%) to approximately 30–50% for metastatic DDLPS and PLPS, with retroperitoneal location conferring dramatically worse outcomes than extremity location due to the inability to achieve wide surgical margins against retroperitoneal structures. The foundational treatment paradigm is wide surgical resection with histologically negative margins — achievable in the majority of extremity cases but frequently impossible in retroperitoneal locations where the aorta, vena cava, ureters, and bowel mesentery constrain resection geometry — supplemented by neoadjuvant or adjuvant IMRT (particularly for extremity and retroperitoneal DDLPS where radiation reduces local recurrence risk), anthracycline-based chemotherapy (doxorubicin ± ifosfamide for DDLPS and PLPS with metastatic or unresectable disease), and emerging molecularly targeted therapies including CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) for MDM2/CDK4-amplified WDLPS and DDLPS (exploiting the CDK4 amplification that drives cell cycle dysregulation), and MDM2 inhibitors (milademetan, navtemadlin) targeting the MDM2 overexpression that suppresses wild-type TP53 in MDM2-amplified liposarcoma, representing a mechanistically grounded therapeutic strategy for the most common molecular subset of the disease. Surgical oncologists performing compartmental retroperitoneal resection or limb-sparing wide excision for extremity liposarcoma, radiation oncologists delivering preoperative IMRT for extremity and retroperitoneal tumors, medical oncologists managing doxorubicin/ifosfamide chemotherapy for metastatic DDLPS and PLPS, molecular pathologists confirming MDM2 amplification by FISH or CDK4 amplification by next-generation sequencing, and investigators enrolling patients in CDK4/6 inhibitor and MDM2 inhibitor clinical trials all coordinate care across one of the most molecularly stratified and surgically complex sarcoma management programs in adult oncology.
Liposarcoma technology platforms — whether supporting surgical oncology programs coordinating compartmental retroperitoneal resection (where the scope of resection encompasses adjacent organ removal including nephrectomy, colectomy, and psoas muscle resection to achieve macroscopic clearance of a retroperitoneal WDLPS or DDLPS that may span 20–30 cm and engulf retroperitoneal neurovascular structures) or limb-sparing wide excision with endoprosthetic reconstruction for extremity liposarcoma, radiation oncology programs delivering preoperative IMRT for retroperitoneal liposarcoma (using intensity-modulated fields to deliver 45–50.4 Gy to the pre-operative tumor volume while sparing adjacent kidney, bowel, and spinal cord within critical dose constraints) or postoperative radiation for extremity DDLPS (50–66 Gy with margin constraints critical for femoral nerve, popliteal fossa, and skin sparing), medical oncology programs managing doxorubicin-based anthracycline chemotherapy (with cumulative cardiotoxicity tracking critical for patients receiving repeat-line anthracycline in the metastatic setting) and ifosfamide-based regimens (with hemorrhagic cystitis prevention protocols), molecular diagnostics laboratories performing MDM2 and CDK4 FISH amplification testing (the molecular confirmation required for WDLPS/DDLPS diagnosis and CDK4/6 inhibitor eligibility) and FUS-DDIT3 fusion testing by FISH or RNA-based next-generation sequencing (the molecular signature that confirms myxoid liposarcoma and opens eligibility for trabectedin), CDK4/6 inhibitor management programs tracking adverse effects (neutropenia, hepatotoxicity, QTc prolongation) and tumor response documentation, MDM2 inhibitor trial platforms managing nausea and thrombocytopenia monitoring, retroperitoneal sarcoma multidisciplinary tumor board coordination programs integrating surgical, radiation, and medical oncology decision-making for a disease where treatment sequencing critically determines resectability and margin quality, or patient portals supporting liposarcoma patients and families managing complex multimodal treatment courses — must maintain the availability and performance standards that liposarcoma's molecular subtype complexity, retroperitoneal surgical scope, radiation-surgery sequencing requirements, and targeted therapy eligibility determination demands. This guide explains why liposarcoma tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the surgical complexity, radiation sequencing, molecular diagnostics depth, and targeted therapy management of modern liposarcoma care.
Why Liposarcoma Tech Platforms Require Specialized Monitoring Attention
Liposarcoma management is defined by complex retroperitoneal and extremity surgery, preoperative and postoperative IMRT with organ-sparing constraints, MDM2/CDK4 and FUS-DDIT3 molecular diagnostics for subtype confirmation and targeted therapy eligibility, anthracycline-based chemotherapy with cumulative dose tracking, CDK4/6 inhibitor and MDM2 inhibitor targeted therapy management, and multidisciplinary tumor board coordination. Technology failures in any of these areas create disruptions calibrated to the surgical complexity and molecular diagnostic requirements unique to liposarcoma management.
Retroperitoneal and extremity surgical planning platforms have direct operative consequence. Compartmental retroperitoneal resection for WDLPS and DDLPS — the only potentially curative intervention for a disease where local recurrence drives most liposarcoma-related mortality in the retroperitoneal subtype — requires platforms managing pre-operative CT and MRI tumor mapping records, adjacent organ involvement assessment documentation (kidney, ureter, colon, psoas, vascular structures), intraoperative frozen section margin analysis routing, operative planning documentation for en bloc organ resection, and post-operative complication surveillance. Wide excision for extremity liposarcoma requires platforms managing MRI-based compartmental anatomy and tumor margin planning, nerve and vessel proximity documentation, and limb-function preservation strategy records. Monitor surgical planning platforms at 1-minute intervals during business hours and operative windows.
Preoperative IMRT platforms must be available throughout radiation-surgery sequencing. Preoperative IMRT for retroperitoneal liposarcoma — where delivery of 45–50.4 Gy before surgical resection reduces the size of the high-dose field by treating the pre-operative rather than post-operative tumor bed, lowering adjacent bowel and kidney dose — requires platforms managing treatment planning records, critical structure dose constraint documentation (contralateral kidney function preservation critical when ipsilateral nephrectomy is planned, bowel dose constraints), daily delivery verification records, and pre-operative tumor response assessment documentation. Postoperative IMRT for extremity liposarcoma (50–66 Gy with complex field shaping to spare femoral nerves, popliteal structures, and skin) similarly requires continuous platform access. Monitor IMRT planning and delivery platforms at 1-minute intervals during active treatment sessions.
MDM2/CDK4 and FUS-DDIT3 molecular diagnostics platforms drive subtype confirmation and targeted therapy eligibility. MDM2 amplification — confirmed by FISH showing high-level MDM2 gene copy number gain relative to chromosome 12 centromere, or by RNA-based NGS demonstrating MDM2 overexpression and amplification — is required to confirm WDLPS or DDLPS diagnosis (differentiating WDLPS from benign lipoma, and DDLPS from other high-grade sarcomas), to determine CDK4/6 inhibitor eligibility in the metastatic setting, and to establish eligibility for MDM2 inhibitor trials. FUS-DDIT3 fusion confirmation by FISH or RT-PCR/RNA-seq is required to confirm myxoid liposarcoma diagnosis and trabectedin eligibility. Platforms managing molecular diagnostic test ordering, FISH result routing, NGS panel result access, subtype documentation, and clinical trial eligibility records cannot fail during active diagnostic and treatment planning workflows. Monitor molecular diagnostics platforms at 1-minute intervals during business hours.
CDK4/6 inhibitor management platforms coordinate novel targeted therapy cycles. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) in MDM2/CDK4-amplified WDLPS and DDLPS require platforms managing dosing records, adverse effect surveillance (Grade 3/4 neutropenia requiring dose interruption in approximately 30–40% of patients, hepatotoxicity, QTc prolongation for ribociclib), CBC monitoring schedule documentation, and tumor response assessment records. Monitor CDK4/6 inhibitor management platforms at 1-minute intervals during business hours.
Anthracycline chemotherapy management platforms require cumulative dose tracking. Doxorubicin-based chemotherapy for metastatic DDLPS and PLPS — delivered as doxorubicin monotherapy or doxorubicin/ifosfamide combination — requires platforms managing cumulative anthracycline dose tracking (with cardiotoxicity threshold monitoring, particularly in patients receiving second-line or third-line anthracycline retreatment), echocardiographic cardiac surveillance scheduling, mesna and hyperhydration protocol documentation for ifosfamide-containing regimens, and cycle timing records. Monitor anthracycline chemotherapy management platforms at 1-minute intervals during business hours and active administration sessions.
Multidisciplinary tumor board coordination platforms integrate surgical, radiation, and medical oncology decisions. Retroperitoneal liposarcoma management requires multidisciplinary coordination of surgical extent (compartmental vs. organ-sparing resection debate), radiation sequencing (neoadjuvant vs. adjuvant vs. no radiation), and systemic therapy sequencing — decisions that require platforms providing simultaneous access to imaging records, pathology reports, molecular diagnostic results, operative histories, and radiation planning documentation. Monitor MDT coordination platforms at 1-minute intervals during business hours.
What to Monitor on a Liposarcoma Tech Platform
Retroperitoneal and Extremity Surgical Planning
Monitor CT and MRI tumor mapping records, adjacent organ involvement documentation, intraoperative frozen section margin routing, en bloc resection planning records, operative complication surveillance documentation, limb-salvage margin and compartment planning records, and post-operative rehabilitation coordination at 1-minute intervals during business hours and operative windows. Alert immediately — surgical planning platform failures during preoperative planning and active operative sessions affect resection margin quality in a disease where margin status is the primary determinant of local recurrence risk.
Preoperative and Postoperative IMRT
Monitor IMRT treatment plan access, retroperitoneal tumor volume and critical structure dose constraint documentation (contralateral kidney, bowel, spinal cord, femoral nerve, skin), preoperative tumor response assessment records, daily delivery verification, field modification records, and treatment completion documentation at 1-minute intervals during active treatment sessions. Alert immediately during active IMRT delivery — retroperitoneal radiation requires daily plan verification against evolving tumor position and adjacent organ geometry.
MDM2/CDK4 and FUS-DDIT3 Molecular Diagnostics
Monitor MDM2 FISH amplification test ordering and result routing, CDK4 FISH and NGS panel results, FUS-DDIT3 fusion FISH and RNA-seq results, subtype confirmation documentation (WDLPS vs. DDLPS vs. MLPS), CDK4/6 inhibitor and trabectedin eligibility records, and clinical trial enrollment documentation at 1-minute intervals during business hours. Alert immediately — molecular diagnostic access failures delay subtype confirmation and targeted therapy eligibility in a disease where subtype determines treatment strategy.
CDK4/6 Inhibitor Targeted Therapy Management
Monitor palbociclib, ribociclib, and abemaciclib dosing and cycle records, CBC monitoring schedule and result documentation, Grade 3/4 neutropenia dose interruption and reduction records, hepatotoxicity and QTc surveillance, tumor response assessment (CT restaging), and trial protocol compliance documentation at 1-minute intervals during business hours. Alert immediately — CDK4/6 inhibitor management failures delay monitoring of hematologic toxicity that requires dose intervention.
Anthracycline Chemotherapy Management
Monitor cumulative doxorubicin dose tracking records, echocardiographic cardiac surveillance scheduling, ifosfamide dosing and mesna premedication protocol documentation, hyperhydration records, cycle timing and dose reduction documentation, and toxicity surveillance (myelosuppression, mucositis, hemorrhagic cystitis, nausea) at 1-minute intervals during business hours and active administration sessions. Alert immediately during active chemotherapy sessions.
Trabectedin and Salvage Systemic Therapy
Monitor trabectedin dosing and hepatotoxicity surveillance records (ALT/AST elevation is common and dose-limiting), gemcitabine/docetaxel salvage regimen documentation, response assessment records, palliative and best supportive care coordination, and clinical trial enrollment for MDM2 inhibitor studies at 1-minute intervals during business hours and active treatment sessions. Alert immediately — salvage therapy documentation failures affect patients with limited treatment options.
Multidisciplinary Tumor Board Coordination
Monitor MDT case presentation record access, imaging and pathology report synchronization, surgical, radiation, and medical oncology decision documentation, retroperitoneal sarcoma referral center coordination records, and treatment plan modification records at 1-minute intervals during business hours. Alert immediately during scheduled tumor board review sessions.
Patient Communication Portal
Monitor patient portal availability for toxicity reporting, appointment coordination, and communication with the care team during active treatment and surveillance phases. Alert on sustained failures during business and evening hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Liposarcoma programs coordinate across surgical oncology, radiation oncology, medical oncology, molecular pathology, cardiology, and radiology — authentication failures simultaneously block every member of a care team managing patients on complex multimodal regimens where molecular diagnostic records, IMRT constraint documentation, and anthracycline dose tracking require continuous, coordinated multi-specialty platform access.
SSL Certificates Across All Domains
Monitor SSL certificate expiry across all patient portals, surgical planning systems, IMRT platforms, molecular diagnostics interfaces, CDK4/6 inhibitor management systems, anthracycline tracking platforms, and tumor board coordination tools. Certificate errors disrupt the treatment planning and molecular diagnostic workflows central to liposarcoma management.
HIPAA and Oncology Data Privacy Considerations
Liposarcoma technology platforms handle sensitive PHI including MDM2 and CDK4 FISH amplification records with molecular subtype and targeted therapy eligibility implications, FUS-DDIT3 fusion diagnostic records, operative records from complex retroperitoneal resection including organ removal documentation and intraoperative margin analysis, IMRT treatment planning records with organ-at-risk dose constraint documentation, cumulative anthracycline dose tracking records with cardiac surveillance data, CDK4/6 inhibitor and MDM2 inhibitor trial enrollment and adverse effect records, and retroperitoneal tumor board deliberation documentation that may encompass sensitive surgical risk and prognosis discussions. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components, including platforms that support care coordination across multiple referring institutions for patients evaluated at retroperitoneal sarcoma specialist centers.
For platforms managing cumulative anthracycline dose records — where documentation failures could contribute to inadvertent cardiotoxic overexposure — data availability standards must reflect the patient safety dependency of cardiac monitoring in patients who may receive anthracycline across multiple lines of therapy. For platforms managing MDM2 molecular diagnostic records that determine trial eligibility for patients with limited treatment options, data availability standards must match the clinical significance of these records to patients with advanced liposarcoma. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for liposarcoma programs managing oncology PHI across surgical, radiation, and systemic therapy phases.
Alerting Strategy for Liposarcoma Tech Platforms
Immediate alerting 24/7: Authentication and core platform access. Liposarcoma patients on active chemotherapy or targeted therapy may require urgent care team access outside business hours for toxicity management.
Immediate alerting during treatment sessions: IMRT planning and delivery platforms during active radiation sessions; anthracycline and ifosfamide chemotherapy management during active administration; CDK4/6 inhibitor management during active cycle monitoring. These platforms cannot fail without immediate clinical intervention.
Immediate business-hours alert: MDM2/CDK4 and FUS-DDIT3 molecular diagnostics (subtype confirmation and eligibility decisions), retroperitoneal and extremity surgical planning (during preoperative and operative windows), multidisciplinary tumor board coordination, trabectedin and salvage therapy management, and CDK4/6 inhibitor adverse effect surveillance. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Patient communication portal, post-treatment surveillance imaging scheduling, and late recurrence monitoring. Alert when failures persist beyond a single workflow cycle.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms liposarcoma platform availability from the geographies where retroperitoneal sarcoma specialist centers, radiation oncology programs, and systemic therapy infusion suites access the system — important for platforms supporting patients who travel to specialist sarcoma centers for retroperitoneal resection or MDM2 inhibitor trial enrollment and return to regional institutions for ongoing chemotherapy and surveillance.
Status Page for Liposarcoma Care Team Communication
A real-time status page gives surgical oncologists planning compartmental retroperitoneal resection, radiation oncologists delivering preoperative IMRT with renal dose constraints, medical oncologists managing CDK4/6 inhibitor cycles and anthracycline cardiotoxicity surveillance, molecular pathologists routing MDM2 FISH results, radiologists reading post-operative and surveillance CT studies, and tumor board coordinators managing retroperitoneal sarcoma multidisciplinary review immediate platform visibility without requiring inbound IT support contact. During an IMRT delivery platform outage during a scheduled preoperative radiation session for a retroperitoneal DDLPS patient approaching surgical resection, a status page enables the radiation oncology team to immediately activate treatment postponement protocols and communicate the delay to the surgical planning team before the operative window is affected.
Include the status page URL in IMRT treatment downtime procedures, retroperitoneal resection planning contingency workflows, CDK4/6 inhibitor management fallback protocols, anthracycline administration downtime procedures, and molecular diagnostics emergency access workflows.
Vigilmon Setup for Liposarcoma Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Retroperitoneal / extremity surgical planning (operative hours) | 1 min | Slack + PagerDuty (surgical hours) | | Preoperative and postoperative IMRT (treatment sessions) | 1 min | Slack + PagerDuty (treatment hours) | | MDM2 / CDK4 / FUS-DDIT3 molecular diagnostics | 1 min | Slack + PagerDuty (business hours) | | CDK4/6 inhibitor targeted therapy management | 1 min | Slack + PagerDuty (business hours) | | Anthracycline chemotherapy management (treatment sessions) | 1 min | Slack + PagerDuty (treatment hours) | | Trabectedin / salvage systemic therapy management | 1 min | Slack + PagerDuty (business hours) | | Multidisciplinary tumor board coordination | 1 min | Slack + PagerDuty (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | Post-treatment surveillance imaging | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure retroperitoneal and extremity surgical planning with immediate alerting during operative windows
- Add preoperative and postoperative IMRT delivery with immediate alerting during active treatment sessions
- Configure MDM2, CDK4, and FUS-DDIT3 molecular diagnostics with immediate business-hours alerting
- Add CDK4/6 inhibitor targeted therapy management with immediate business-hours alerting for toxicity surveillance
- Configure anthracycline chemotherapy management with immediate alerting during active administration sessions
- Add trabectedin and salvage systemic therapy management with immediate business-hours alerting
- Configure multidisciplinary tumor board coordination with immediate alerting during scheduled MDT review sessions
- Add patient communication portal monitoring for treatment and toxicity reporting access
- Configure post-treatment surveillance imaging scheduling with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, patient-facing, surgical planning, IMRT, molecular diagnostics, and chemotherapy management domains
- Add the status page URL to IMRT treatment downtime procedures, retroperitoneal surgical planning contingency workflows, and CDK4/6 inhibitor management fallback protocols
Conclusion
Liposarcoma technology platforms are embedded in clinical decisions where surgical planning platform availability during preoperative workup for a compartmental retroperitoneal resection of a 25-centimeter dedifferentiated liposarcoma determines whether the surgical oncologist coordinating an en bloc resection planned to include ipsilateral nephrectomy, partial colectomy, and psoas muscle excision can access the MDM2 FISH result that confirms the molecular diagnosis, the pre-operative CT volumetric reconstruction that defines the surgical field geometry, and the contralateral renal function documentation that confirms sufficient renal reserve to proceed with planned ipsilateral nephrectomy — all of which must be simultaneously accessible in the operating room and the preoperative planning session if the surgical team is to execute the compartmental resection approach that represents the only proven strategy for reducing the relentless retroperitoneal recurrence rate that otherwise defines the natural history of retroperitoneal dedifferentiated liposarcoma — where preoperative IMRT platform availability during active radiation delivery for a patient completing a 25-fraction retroperitoneal course before surgical resection determines whether the radiation oncologist can verify the daily adaptive repositioning that ensures the 50.4 Gy dose targeting the pre-operative tumor volume concentrates on the DDLPS while the contralateral kidney — scheduled for function preservation in a patient for whom ipsilateral nephrectomy is planned — receives a mean dose within the constraint that protects long-term renal function across the years of surveillance that follow curative resection of a disease with 50% local recurrence risk at 5 years — and where CDK4/6 inhibitor management platform availability during active palbociclib cycle monitoring for a patient with metastatic MDM2-amplified WDLPS determines whether the oncologist reviewing the CBC result showing Grade 3 neutropenia can access the dosing and prior cycle records that allow a real-time dose interruption decision that prevents a septic complication during treatment with a molecularly targeted agent representing one of the few active systemic options in a disease historically refractory to conventional chemotherapy. A surgical planning platform inaccessible the morning of a scheduled compartmental retroperitoneal resection, an IMRT delivery platform unavailable during a preoperative radiation session when the kidney sparing constraint has not been verified for the day's fraction, a molecular diagnostics platform inaccessible when MDM2 amplification status determines eligibility for a CDK4/6 inhibitor trial representing the most mechanistically rational available therapy for a patient with unresectable retroperitoneal DDLPS — these are not IT incidents. They are clinical disruptions in the management of the most common adult soft tissue sarcoma, where platform availability shapes the surgical margin quality that determines recurrence risk, the radiation precision that protects renal function across decades of post-operative survival, and the molecular diagnostic access that determines whether a patient with advanced liposarcoma can access the targeted therapy mechanism most directly matched to their tumor's dominant oncogenic driver.
Uptime monitoring gives liposarcoma tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to surgical oncology programs, retroperitoneal sarcoma specialist centers, radiation oncology departments, and compliance auditors that the platform's operational reliability matches the surgical complexity, IMRT precision, molecular diagnostic depth, and targeted therapy management of modern liposarcoma care.
Start monitoring your liposarcoma tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #liposarcoma #softtissuesarcoma #retroperitonealsarcoma #MDM2 #CDK4 #FUSDDIT3 #myxoidliposarcoma #dedifferentiatedliposarcoma #WDLPS #DDLPS #CDK4inhibitor #trabectedin #IMRT #anthracycline #moleculardiagnostics #multidisciplinaryoncology #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre